Urica Therapeutics, Inc. (Urica) is a majority-owned subsidiary of Fortress Biotech, Inc. (Nasdaq: FBIO) and originally licensed dotinurad, a novel urate transporter (URAT1) inhibitor from Fuji Yakuhin Co. Ltd. in 2021.
In July 2024, Urica entered into an asset purchase agreement, royalty agreement, and related agreements with Crystalys Therapeutics, Inc. (Crystalys) whereby Urica transferred rights to dotinurad and related intellectual property, license and agreements to Crystalys. For more information, please click here.
In October 2025, Crystalys announced that it closed a $205 million Series A financing to support the advancement of two global Phase 3 clinical studies evaluating dotinurad, a next-generation, once daily oral, URAT1 inhibitor with potential for best-in-class safety and efficacy for the treatment of gout. Also in October 2025, Crystalys dosed the first patients in its two randomized, double-blind, multicenter global Phase 3 trials, the RUBY study (NCT07089875) and the TOPAZ study (NCT07089888), evaluating dotinurad for the treatment of gout.
Scroll to top
